Skip to main content
. 2017 Sep 13;18(9):1968. doi: 10.3390/ijms18091968

Figure 8.

Figure 8

In vivo potency of IRCR201 in c-Met-expressing tumor xenograft models. (a) IRCR201 was dosed intravenously twice a week at 3 mg/kg in an A549 non-small cell lung cancer (NSCLC) xenograft model, as compared with the PBS-treated group or huOA5D5.v2-treated group; (b) IRCR201 was intravenously injected at 3 or 15 mg/kg twice a week in an MKN45 gastric cancer xenograft model compared with the PBS-treated group or huOA5D5.v2-treated group. Six mice per group were used for the A549 and MKN45 studies. Asterisks (*) indicate p-values versus PBS-treated group (vehicle group) according to one-tailed two-sample t-test. p-Value < 0.05 was considered statistically significant. (** p < 0.01, *** p < 0.001).